Akari Therapeutics Plc (AKTX) stock
AKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$5.70−0.81 (-12.44%)
Close on Nov 17, 2026Market cap $11.10MP/E –Yield –
Akari Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
No ev/ebitda figures for Akari Therapeutics
Akari Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?